## The Making of eHRSS in Hong Kong eHealth In Action

10 Nov 2015



Chief Manager (eHealth Record)

## 1990+

**HA CMS - Departmental** 

# 1996 HA CMS - Clinical

## 2000 HA ePR

## 2006

PPI-ePR

## 




## Agenda

What makes eHRSS special in the world?


What we build?

What next?

## **HK Healthcare Systems**




#### **Hospital Beds**




27,000 (42 HA Hospitals

3,900 (11 Private Hospitals)



## 21st Century Health Challenges

- 1. Aging population
- 2. Health expenditure
- 3. Scare health resources
- 4. Quality and safety issues
- 5. Efficiency improvement
- 6. Technological advancement
- 7. Public and private partnership



Government take the lead in the development of the infrastructure for sharing electronic health records in both the public and private sectors, in partnership with the healthcare professions in both sectors...

Develop a territory-wide electronic health record sharing system, which save medical costs, minimize errors and safeguard patients' health...

This electronic system will underpin the reform of our primary healthcare services...



羣策創新天

## Electronic Health Record Sharing System (eHRSS)



## 4 Steps for Meaningful Data Sharing

Computer -isation

Standardisation Willing to Use

Willing to Share

## What makes eHRSS special?

## **Government led project**



## **Opt-In Model**

PracticalityThe Essence of eHealth Record Sharing System

Dr Hon Leung Ka-lau Legislative Councillor (Medical)



## **Standard-based Sharing**




eHealth Solutions in Practice

To allow different healthcare IT systems to communicate via the eHR Sharing System, standards such as clinical terminologies and technical specification must be established.

Mr Michael Fung: Chief Systems Manager (eHR), Hospital Authority

## **Recognised Terminologies**



## **Drug Standardisation**

#### Augmentin 375 mg Tablets



Sigma Pharmaceuticals Pty Ltd manufacture
GlaxoSmithKline HK-16677 certificate holder

	-			-0	2	Ē	100	H			1	-	AI	35	C	F	0	E.	
	-		e mile all	No.of		Strength	Strength	Strangth	Strength	Rome of	Dise	TIPLS	August 10 miles	0.45	4.77	Piece of	tio at	Component	1
	HK frg.	Product (sema	Propass 3 Trade Plains	Active Ingredien	Active ingrestient	hhoeeure Vervo	Messare	Dote	Disce With	Admin.	Form	Chara	PRES Care Holder	Park Size	Name of menunections	neo describing	Compare		Refer
1		AR WAS KING THE CHEW, FOL	V21007-200-6		10 COLECALDIFEACT	30	46		1 tablet	Oral	Chavable	D)			E NEOCHE/ PHARLIACELTICA			1 Whole Product	
35		APPRIAL KING TAB CHEJI FIL			IO THAN NEHYDROHLDADE	5.2	mg .		1 tablet	Desi	Chevable				IE NEUCHEM PHARMACEUTICA			C. Whole Product	
32		\$200 NEX TAB 300 MG	sout her		1 THURSDLE	500			1 19041	Cra	-	Di .	STAR LIEDICALSUF		MEDICHEMIFUTO.	Okoline		I Whole Product	
25		EVANS IN 200 CAP 200 IU. GUIONE INVICATION SOLA L.S.	ENANG.		1 WTAMIN EAST ACHATROOPH 1 STAMB	290	16/W/0		T catarie	Urstaral		NP NP	HOSPILA DALTED	CESTIE	HOSPIACHEAUTH RUST AS &	USA.		1 Whole Product 1 Whole product	
2			STICHE ON		16. CHANGCOBALAMIN		mes		acres .	Deal	Capacia	MP	CY LOEN HOP LTD		PLD SCHENED GMBH & CO. A.			C Whole Product	
100			STRONG-GH		is DIGBIG YOUDER		TE		- pageties	One	Capeure	No.	CHUIEN HOP LITE		P.P. SCHERER GIVEN & CO. N			I Whole Product	
50		THE NO-DARK	STIGNE GT		LE VITAMIN EVAS DU AUPHA TOCOPE		-5		L cape e	Desi	Capping	NP	KY LUEW HOP LTD.		N.F. SCHEREN GMEH & CO. #			I Whole Product	
30		\$19.01/G-G (N G)2-	STRONG-GHI		15 ACCURRICACIO	47.8	TIS		L tapet a	Oral.	Capture	SP	k FLUEN HOP CID		RIP, SCHESER GIVEN & OIL N			1 Whole Product	E DHH4
50	H480806	STIENG ON CAP	STICKES IN		TE MADONNEHADESCHTDER		mg .		L capeus	Chal	Capaula	NP	KY LUER HOP LTD		R.C. SCHERED GMBH & QD. A.			2. Whole Product	
ناها	K Keg		STRONG-GH		16 1 BOFLAVA		75		1 pageties	Ora	Capeus	NP	CHUEN HOP CTD		P.F. SCHERER GIVEN & QD. N			I Whole Product	
85	HISCEUS	MUNICAL PROPERTY.	STRENG-GH STRONG-GH		LE NOSTINAMES LE NOTASSION IODIDE		-15		I cape e	Drail Ora	Capaula	NP NP	KY LUEN HOP LTD.		RIP, SCHERED GMEH & CO. # RIP, SCHERED GMEH & CO. #			1 Whole Product 1 Whole Product	
nu	mbei	TIENG ON CAP	STIGNG-GY		16. CALCIUM SANTOTHENATE	9,03	75		Logsus	Draf	Capeus	MP	RY LUEN HOP LTD		R.D. SCHEIED GMBH & CO.A.			C. Whole Product	
20	H130806	RONG-ON CAS	STILONG-GI		16 CALCOUN ACCORBATE	37.8			- pageties	Ora	Capacia	No.	CHUIEN HOP CTD		P.P. SCHERER GIVEN & CO. N			I Whole Product	
E.	HI30505	TIGHT ON CIT	mous ch		15 THAMMENTRATE		-5		L capra e	Desi	Capacia	NP	KYLUEN HOP LTD		NEC SCHEREN GMBH & CO. #			I Whole Product	
8-	H130605		STRONG-GH		15 CHOLINESTANTIATE		ms.		L repris	Ora.	Capture	SP	RY WEN HOP CID		RIP, SCHERER GIVEN & CO. N			1 Whole Product	E DHH4
70		STIENG ON DIS	STICKS CH		16. VITALIM A	5000	14		L capeus	Del	Capaula	NP	KY LUER HOP LTD		RLS. SCHERED GMBH & QD. A.			5. Whole Product	
(1)	H130608	Product	Proposed		16 ADMINELLY		75		i papaties	Ora		NP	CHUSEN HOP CTD		R.F. SCHEIER GIVEN & QD, N			I Whole Product	
4		Product	Proposed		15 MAGRIEUN SULFATE		75		Lapsus	Desi	- Free Pro-	NE	S.Y.LUEN HOP LTD		N.C. SCHERED CMEH & QU. #			I Whole Product	
-7	#130e06 . #185365	Name T	rade Name	2	16 COLECULOPEACL 1 CSPLATA ●	600			1 120001	Oral.	Capture	SP Declar	A FLUEN HOP CTD	200 MC / 100 M 20	R.P. SCHERER GIVEN & 03, II I EBEWE PHARMA GESLM BH:			2 Whole Product	
2			CARABLOCK 400		1 NOVEDNAN	1	75	/	hour	Ora	ablar		S NOMAN IS MARKING S STAG LIEDVOAL SUFF		MEDICHEME UTO	CYTRUS		I Wholeproduct	
16		ADMANCE NO 1 CREAM	ACMANCENCAL		4 CLOTHWAZOLE	1	Same	1/2	1	Todas	Crasins				M ADVANCE PHAIMACEUTICAL			I Wholeproduct	
D		ADVANCE NO A CREAK	ADVANCENDS.		A BETAMETH ADDISTALEMATE		Kink	1//		Topics	Creari				LI ABVANCE I-AU NOBUT CAL			1 Wholeproduct	
-1		ADMANCE NO.1 CAEAM	ADVANCENG.1		4 CENTAMON SULFATE	5.2		V		Topics	Craemi				V ADVANCE PHARMACEUTICAL			5. Wholepropert	
3			XDVA-CENGS		4 C.ODU \OL	-	KNO.	W		op est	Cream				LI ABVANCED-ADVINCEUTICAL			I Wholsprospet	
30			DHAHU		E EEEFLANN	23	75		/ uni	-	ablat	NP	SATE PHARMACEUR		SATO PHARMACELTICAL CO.,			I Wholeproduct	
8		BIHANUTAS BIHANUTAS	No. of act	πve	Active	Stren	gtn +	· unit	: /- uni	123	stint	NP NP	SATO PHARMACEUM SATO PHARMACEUM		SATO PHARMACEUTICAL CO., SATO PHARMACEUTICAL CO.			1 Vinoleproduct	- C
8		BIHANU TAB		-	THE PLUS ALL PRODUCTIONS	29	neasi		1 12/2/01	1	Teblet	No.	SATO PHARMACEUT		SATO PHANNACEUTICAL CO.			2. Wholepropert  I. Wholepropert	
34		SHANUTAS	ingredie	กเร	Ingredient	01.1	neasi	ure +	umit		Tables	NE	SATO PHARMACEUT		SATO PHARMACEUTICAL CO.			I Wholeproduct	
33		STAR MEDIC NATURAL ROSE H			2 AUGUSTONCO	200	75	- 1	1 10041	Ora.	SDIM:	SP	WATERWITE		SOUN MADELATORES, NO.	USA.		1 Wholsproduct	
36	H140560	CTAS) MEDIC NATURAL ROSE H	STAN MEDIC NATURAL ROSE HAS	4	2. ADSE +4PS	150			. I tablet	2	Table	MP	VIMITECK INTERNATIO	BNAL CO	SOMA LABORATORES, INC.	JSA		5. Wholspropuct	рни:
8.		800 - 811 CAP (+EEUKE) 81			7 MICOTINALINGS		75		i pageties	Of	Capeule	NP	KNULEN HOP CID	200	P. P. SCHELET GALLET & CO. 4			I Whole Product	
33		BCO - BIT CAP   HEBUKEN BIL			7 CHANGCOBALAMIN		mes		Lagrage	1-	Lapaus	NP	S.Y.LUEN HOP LTD.		N. P. SCHEDEN CHIEF & CO. N			I Whole Product	
泰		BCO - B11 CAPIFEEUFEF BL			2 SHRIDDXINE HYDXOCHLOX.D€		TIS		L report to	Ors	Capture	SP	k " WEN HOP CITO		R. P. SCHELET CATER 8, 80, 4			2 Vincia Product	
30		600 - 611 CAP (HEBUKEV BT. 800 - 817 CAP (HEBUKEV BT.			7 RECELIANN 5 CALCUM PRIVIDENCES		75		Lagre	(Drs.)	Capaux	10	KY LUBIN HOP LTD		PLP SCHERENGMEN & CO. 4 PLA SCHERENGMEN & CO. 4			C. Whole Product	
3-		BCO - B11 CAP (HEEDNEY B).			7 BHELVEST	100	75		Logore	Drail .	Capaula	NE	CYLLEN HOP LTD		P. P. SOFEREN GNIEF & CO. S			I Whole Product  I Whole Product	
24		800 - 811 CAP (PEBUKE) BI.			2 THANKEN WE		mg.		Rout			000	e Likepup		R. R. SOHEREN CHIEF & CO. 4			I Whole Product	
3		UTALLIN EAR	WTALUK		7 EWC (AS GLUCCHATE)	13.5			Rout	e or	1.000		NAME OF TAXABLE PARTY.	G-178	LAS DISA VISIDA FALIRE	FRANCE		C. Wholsproduct	
75		VITALLO CAS	ATALIA:		> WGOTHALINDE		TE.		adn	ain	Captur	orn	nucoly Holicatory	OUTD	LASCISA VISION FALAS	PARANCE		I Wholeprocest	
36	+145554	UTALLIF EAP	WINLES		7 MANGARISE (AS GLUCORATE)		-5		-	-	Capping	OI II	ALCON HONG HONG	G-17B	LAS CIBA VISIDA FALIRE	FRANCE		I Wholeproduct	Вниг
2		STALID GAS	ATALUN		2 WITHOUGH E		reg		i repris	10ms	Capture	RP	ALCON HONG HONG		148 CEA VISION FAURS	FRANÇE		1 Wholeproduct	DHH-
88		VITALLIN EAST	WT-64-UK		7 BETACARCTERS		75		Cape	(Des)	South Brown	ND	ALCON HONG HONE		LAB O'BA VISION FAURE	FRANCE		<ol> <li>Wholepropurt</li> </ol>	
52		VITALUS CAS	MALUN		2 SELENIUM		mes.		1 pageties	Ora	Capeus	No.	ALCON HONG NOW		LABORA VIDON PAJAR	PANALYCE		1 Wholeproduct	
-200		UTALLIN CAP	WTALLS UEDIA ELL CODITANI COD LIVER D		1 COD DVSR OL		75		1 capsus	Desi	Capaule	NP	BRACON PIR HAT		LAS DEA VISION FAURE SOFFICE, TECHNOLOGIES NO	FRANCE USA		1 Wholepropert 1 Whole Product	
100			MEDIWELL BUSYMAN C SUPER B.C		15 CHOLASSTATINES		75 75		L tablet	Oral Draf	Capture Tetrat	3	DRAGON DAKANATA		WET COAST SESTING	15		C. Whole Product	
107	-0.4613L		LIEDWELL BUDYMIN-CSUPER B-C		15 NORTOL		75		tablet	Ora	Table!	No	DRAGON AK HAT		WET COAST LABORS	1		I Whole Product	
			MEDINELL BUDYMAN C SUCEP B-C		LE LIVER COMCENTRATE				Litables	Drai		NE	DRAGDING NE (NT)		WEST DOAST LABS INC.	Isa.		1 Whole Product	
			MEDINELL BUSINESS SUPER BLO	d -	LE PANTOTHENICACID (45 CALCUL		ms		1 (1004)	200	PED ME	60	DOLCON, NY HAT.	THOUGHT.	WEST COAST LABOURC	Viel.		1 Whole Product	
			MEDIMELL BUSYMAN COUPED & C		TE MICOUNTAINUE	15	mg .		1 tablet	Desi	Tablet	150	DRAGON ON LOWE		WEST LOAST LABS INC.	USA		J. Whole Product	
	-0.4613L		HEOMEL, BUDYAN, OSUTER B.C		20 F01400604 54 54 54 51. ST		75		1 tablet	Ora	Tables	Nº	DRACON LAKINT		· Manuf	acturer	's	I Whole Product	
	HF45161		MEDINELL BUSYMAN CEUCED B-C		LE RON (AS PERROUS PLANARATE)		-15		Litablet	Dal Le	egal	14	Certificat	te 🖁 🛮 Pacl	WELL - UND ENDO PAC.	U2.R.		1 Whole Product	
			MEDINELL BUSINING SUPER BLO MEDINELL BUSINING SUPER BLO		LE A BOPLAVA LE THAMME HYDROGHLDRIDE		mg.		1 (100-4)	The Later Control		D: 1	DESCRIPTION OF THE PARTY OF THE	THE PERSON NAMED	name -	- place	of I	1 Whole Product	
			LIECTAREL BUDYANA CSUPER B.C		15 ACCURSO ACTO	200			L tablet	Const C	lass	Ø. I	holder	sizes	THE RESERVE AND ADDRESS OF THE PARTY OF THE	Lincolnic		I Whole Product	
	, manee	The state of the s	MEDINELL BUDYMIN CENTER B-C	-	15 Discovers	100			Litables	Drail	Tables	Ø-1	BRAGEN ONE ONT	UTTAR BING OD UTD	ີ manເ	ifacture		1 Whole Pour	
713			A SO WELL BUSYN NUCSUPER B-0		15 FOLIO ACID		men.		L tab et	'Ora	Tables	No.	DRAGON LAK NAT.	מש מט שאר אריין.	WEST DOAST LABOR NO.	ASA.		2 Whole hot uet	
140	HI 45161	MEDIUR LIBUSYMW-C SUPER	MEDIMELL BUSYMMUR SUPER & C	d .	LE CHANGEBEALAMIN	15	meg		1 tablet	(Draf.	Tablet	NP	DRAGON ONE ONT	LITTADING COLUTE	WEST COAST LABS INC.	JSA		I. Who Product	Вни:
			ALECTIVE BUSYNING COURSE BLO		IS BOTH	8	meg		1 tablet	Ora		NP	DRACON JAK NE		WEST COOKST LABOURG.	45A,		Julyou Product	DHH-
412	HF45161	MEDIMET BROWN C 27 LET	MEDINELL BUSINNS CSUCES 3-0	0	TE SANDON MEHADSOCHTOSBE		75		Litablet	Drei		NP	BRADEN ON CONT.		WEST DOAST LINES INC.	USA.		T WAS LAND	DHH2
			LICHOCANE HOUSE LAND LAND	5	1 LCVOOANE HIDACCHLOADS		75		0.60		Solution (		PERE CORPORATIO		APPEAR PERFORM OF LINE ED			roduct	Deliver
			DAT DOBAN BARBIA 608 LIVER O OP. WESTLEY'S SOLARIAM GOOD OF		1 COD DVER GL. 1 COD DVER GL.		mg		L capture	Oral Oral	Capeus		DRAGON JAK HAT		MOTHERLAND INTERNATION.		Р	roduct	D-H
- 27	4492525	DUPRODIA DINTMENT 28	STREET, STREET		1 MUNICON		TS Santa		- paparier	Topics	Dintment		NIDOWAL INVESTINE		GLENMARY PHARMACEUTE		Co	22 12 22 22 22 22	Deet
			THE ISOAY PLANTATION PUPE.		1 TEX 1466 OL		Britis			Top of	Liquidino		DISP HONG YONG		NTECTIA HEALTHCAVE BALL		Cor	mponen	DHH3
		DLEAN & CLEAR ACRE CLEAR A			1 SAUCYL CACC		Sagle			Topics		MP			DE MANUFACTURING LIMITE			info	DHH:
122	HI.36268	DIAN GLICERIN SUPPRORIADI	OKAY-GUYGENIN		1 GLICENCE		5 800			Secre	Supposite		MEDIA MEDITINAT	0	PUBLIC PHARM LAB CO CTD			-	DHH!
:201	+#57065	CETHALENN CTABLA CAP 500M	CEPHALENIN STADA		1 CEFALEXYA	500	mg		L mps. s	Deal	Capping	à	STADA PHARAMAGE		PIMEDHARCO	WETWAN		1 Wholepropled	
178	MI.57412	EUSCABAR DROPS 5%	BISCA		1 CHECANIPHENICOL		SW			Oto: 441			MEDPIECH FAT EAST		STERICON PLANTA ROWATE			1 Wholeproduct	
-25	-HEBBALA	CENTIFLEX-BITAB	CS/TIFLEX-B		12 THAMMEHYDROCHJORDE		mg		Litablet	Onl		MD	ALLUMAS (GERMAN)		WEST COAST LABS INC.	JSA.		L Whole Product	
		CENTILEX 6 TAB CENTILEX 6 TAB	CBYTIPLEX-B		12 CALOUN 12 DON 145 FED TOUS FUNNINATE	95	75		1 tablet	Ora:	Tebrac	No.	ALLWAS CERMAN		WEST COUNT LABOR NO.	45A,		I Whole Product	
- 18	mf 23688	CERTIFICATION INTO	CSM/IRILEX-P		EX INON IAS PERMISUS PUMARATE	18	mir		L bablet	Ural.	abia:	748	ALLUMING (CSIMAR)	MEDICAL CITY	WEST GOAST LABSING	USA		3. Whole Product	EHH2


### **Drug Reference Standards**



NHS Dictionary of Medicines and Devices (dm+d) Editorial Policy August 2010

nehta Australian Medicines Terminology (AMT) Editorial Rules June 2009 SNOMED CT
Editorial Guidelines
May 2008


#### Augmentin TAB 375 MG




## **Chinese Medicine Standardisaton**



### **Computerisation to Standardisation**



### **Chinese Medicine Terminology Standardisation**



#### **Standardisation Processes**

#### 標準化

- 制定標準化的編寫原則 (Editorial Rules)
- 進行病名、證型、治法、腧穴的標準化工作

#### 詞彙配對

- 與其他常用的參考詞彙表的詞彙進行配對(Mapping)
- 配對臨床詞彙的同義詞/別名

#### 詞彙管理

- 制定一套中醫臨床詞彙表(CM Clinical Terminology Table)
- 並制定詞彙表的管理、編寫及修改原則

### **Recognised Terminologies**

註冊中醫簽發病假證明書參考指引 國家標準中醫病證分類與代碼GB/T 15657-1995 國家標準-中醫臨床診療術語疾病部分 GB/T 16751.1-1997 高等醫藥院校教材-上海科學技術出版社、

病名

新世紀全國高等中醫藥院校規劃教材-中國中醫藥出版社中醫藥學高級叢書第二版-人民衛生出版社中醫藥學名詞 2004, 2010及2013-中醫藥學名詞審定委員會中醫大辭典

國家中醫藥行業標準-中醫病證診斷療效標準

證候

世界衛生組織傳統醫學國際疾病分類項目 國家標準中醫病證分類與代碼GB/T 15657-1995

國家標準-中醫臨床診療術語-證候部分 GB/T 16751.2-1997

高等醫藥院校教材-上海科學技術出版社、

新世紀全國高等中醫藥院校規劃教材-中國中醫藥出版社

中醫藥學名詞 2004-中醫藥學名詞審定委員會

中醫大辭典

治法

國家標準-中醫臨床診療術語-治法部分 GB/T 16751.3-1997 中醫藥學高級叢書第二版-人民衛生出版社

中醫藥學名詞 2004 -中醫藥學名詞審定委員會

腧穴

國家標準腧穴名稱與定位GB/T 12346-2006

高等醫藥院校教材-針灸學

世界衛生組織標準針灸經穴定位 (西太平洋地區)

療法

國家標準中醫臨床診療術語-治法部分GB/T 16751.3-1997 高等醫藥院校教材-上海科學技術出版社、

新世紀全國高等中醫藥院校規劃教材-中國中醫藥出版社

中醫藥學名詞 2004 -中醫藥學名詞審定委員會








## **Chinese Medicine Concepts**



## Mapping


- 將術語表中的詞彙與其他 醫療術語編碼的詞彙配對
- 對研究、教學、醫療服務 管理、疾病監察、臨床決 策支援等醫療紀錄的二次 使用有很大幫助。




感冒	<b>或冒</b>													
病假指引	國標 <b>97</b> 的 編號	l <mark>國標97</mark> 的名 稱	國標95的編號	國標 <b>95</b> 的 名稱	五版教材 上海科學 技術出版 社	七版教材 中國中醫藥 出版社	中醫藥學名詞編號	中醫藥學名詞 名稱	世衛編號	世衙名稱				
感冒	21.1	感冒	BNW010	感冒病	感冒	感冒	1-1.2463	感冒	3.1.7	感冒				

## What we finally build?

### **Electronic Health Record**




### **Sharable Data**




## What next?

#### Meaningful Use of eHealth



#### Meaningful Use of eHealth




## CMS On-ramp in Practice

The overall workflow in the outpatient department has been very smooth and efficient with the implementation of CMS On-ramp.


Dr Anne Kwan Hospital Superintendent of Evangel Hospital




# **Hospital - Discharge Summary**



## **Clinic - Consultation Note**




## Meaningful Use of eHealth







### Augmentin TAB 375 MG




HK-16677

Augmentin TAB 375 MG







HK-27421

AUGMENTIN FOR IV INJ 1.2G/VIAL



amoxicillin (as sodium) 1 g + clavulanate (as potassium) 200 mg per vial

HK Reg	ingredient	ingredient	ingredient strength unit	ingredient unit of	ingredient unit of measure unit
27421	1 amoxicillin (as sodium)	1	g	1	vial
27421	1 clavulanate (as potassium)	200	mg	1	vial

"TWO tablets of HK-44207 would give 1 g of amoxicillin"...

HK-44027

HK-44027 AUGMENTIN TAB 625MG



amoxicillin (as trihydrate) 500 mg+ clavulanate (as potassium) 125 mgPer 1 tablet

HK Reg	ınit	ingredient	ingredient	ingredient strength unit	ingredient unit of ingredient unit of		
HK Keg	group -		strength value		▼ measure value	measure unit	
44027	1	amoxicillin (as trihydrate)	500 mg			1 tablet	
44027	1	clavulanate (as potassium)	1	.25 mg		1 tablet	
44027	1	ciavulanate (as potassium)	.1	.25 mg		1 tablet	

# Better eHealth drug record

A more structured and standardised dose instruction information on eHR allowing better communication between healthcare providers

# System-friendly transmissible information


Transmit drug regimen

# Potentiate advanced medication process


Repeat prescription
Electronic prescribing
Medication Reconciliation

#### Facilitate Public-Private Partnership

Granularised dose instruction potentially allows transmission of drug order between HCPs (e.g. from doctor's clinic to pharmacy)



## Meaningful Use of eHealth






# Patients' Support and Concerns over eHealth Record Sharing

Mr Pang Hung-cheong


Community Organiser of Society for Community Organisation

# **Patient Portal**





## Meaningful Use of eHealth





With the eHR Sharing System in place, the transparency of diagnosis will be enhanced, which unquestionably is in patients' favour.

Prof Fok Tai-fai:

Pro-Vice-Chancellor and Professor of Paediatrics Chinese University of Hong Kong


# Public-Private Interface—Electronic Patient Record Sharing Pilot Project (PPI-ePR)

- Launched in April 2006
- Sharing of clinical information between HA and private sector
- Utmost importance for success of PPP
- A prelude to eHR

460,000 patients
4,000 doctors and nurses



# **Public – Private Partnership**



## 普通科門診公私營協作計劃

General Outpatient Clinic Public-Private Partnership Programme

於觀塘 黃大仙 屯門推行 Wong Tai Sin

#### 計劃對景

- ▶ 警告局普通科門診病人
- ■病情應定的高血量(或附帶高血脂症)患者
- 計劃稍後會延伸至無尿病患者
- ◆ 台資格的病人將收到醫管局的邀請信 類人無關目行申請

#### Target Patients

- HA GOPC patients
- Canically stable patients having hypertencion with or without hyperficidents
- To imite patients with diabetes mellitus in later phase
- Eligible patients will receive invitation letters from HA and do not need to apply by themselves

#### 計劃特贴

- 病人可從參加計劃的私家醫生名單中辣潤一位作為家庭醫生
- 每年十次資助門診服務,包括慢性疾病和傳發性疾病的診症及其相關的藥物
- 可經參加計劃的私家醫生轉介接受由醫管局提供特定的相關化驗和X完檢查服務

#### Programme Features

- Patient can select a private doctor from the participating private doctor list as family doctor
- Up to 10 subsidised consultations per year, including consultations and drugs for treating chronic conditions and opisodic illnesses
- Relevant investigations will be provided by HA as specified through participating private doctors' referral







#### 縮短病人手術輪候時間

Shorter waiting time

一次過定額資助5,000港元予每宗由私家醫生進行的白內障手術

A one-off, maximum subsidy of \$5,000 to patients for entaract surgery provided by private aphthalmologists.

#### 覆邀參加病人 Invited Target


場正於醫院管理局輪模自內除手術 而又被診斷為題合接受 局部無難手動的非治症日內障病人。

Peliane with the authority to Hoppital Authority hospitals' routing waiting less for entired surgery for the loggest period and only sequine, local immeshiesis obtained surgery.

#### 邀請過程 Invitation Process

醫院管理局分階政務信 邀請等信息長時間的病人多如… 注意:實人養育自行申請

MA shall issue certation fathers to invite patients in batches, recording to their validing line. Note: There is no mode for patients to publy on themselves.



#### 日標

- 加強為末期緊急場前人 所提供的血液透析服務
- 提升病人自我照顧能力。 提高生活資素
- 加強與社區監查機構 在病人護理上 的合作

#### Objectives

- · Enhance hasmodialysis service for ESPF patents
- . Enhance patients selfcare capacity and improve their quality of life
  - Enhance collaboration between HA and community medical



#### 背景

為讓更多有需要的未期賢良場病人獲得 血液透析服務、醫院管理局(儘管局)推出 **『共析計画』 - 異社區醫療機構補手** 我用公私营会作模式、增加血液适析服務名额。 篡在人在社區中接受治理。

#### Background

To case for the growing demand of the haemodalysis service for end-stage renal tallure. IESREI patients, the Hospital Authority (HA) octagorates with community medical organisations. to provide options for patients to receive has modalysis in the community. under the Haemodia vais Public Private Parmeship

#### 推行日期

Programme

2010年3月

Launch Date March 2010

#### 公私營合作 廣人多選擇

整管局與社區越級機構合作, 獲邀或人 可循揮於社區血液透析中心接受治療。

#### Public-Private Partnership More Choice for Patients

HA collaborates with community medical organisations. to invite cirrically suitable patients to join the Programme which offers the choice of receiving treatment in community haemodialysis centres.

#### 目標對象

緊管固合推請下列合資格病人 多加能計劃:

- 項正於器管局接受直導域析腳絡 页属情種定的病人;
  - 末期開表域,但不能接受機謀 透析的新症病人;或
    - + 現正接受腹膜護折 但有治療失效围险 的演人

#### **Target Patients**

HA will invite the following: groups of clinically suitable patients to participate in the Programme :

- . Patients who are currently on heemodialysis in HA hospitals and in stable condition;
- . Newly diagnosed ESRF patients who are not suitable for peritorical dialysis; or
- + Pentoneal dialysis patients at risk of treatment tallura





#### 穩中求變 務實為民

Seek Change

Maintain Stability

Serve the People with

Pragmatism

# Twin-Track System for Public and Private Healthcare Sectors

Future development of Chinese Medicine industry



Sustainable healthcare financing model





# CREATIVITY IS THINKING UP NEW THINGS INNOVATION IS DOING NEW THINGS



Theodore Levitt

Data

Innovation is taking two things that already exist and putting them together in a new way

Tom Freston



